← Ablatotech Vitals
Nephrology EvidenceDigest

Emerging Evidence on the Use of Anti-CD73 Therapies for Treatment-Resistant Lupus Nephritis

Nephrology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
November 17, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Anti-CD73 therapies represent a novel immunomodulatory approach under investigation for treatment-resistant lupus nephritis (LN), a subset of patients who fail to respond adequately to conventional immunosuppression. Early preclinical and emerging clinical data suggest that targeting CD73, an ecto-5'-nucleotidase involved in adenosine generation and immune regulation, may reduce renal inflammation and fibrosis. However, clinical evidence remains preliminary and limited, warranting cautious interpretation. Anti-CD73 agents are not yet part of standard care but may become adjunctive options for refractory LN pending further validation.

Clinical bottom line

Anti-CD73 therapies represent a novel immunomodulatory approach under investigation for treatment-resistant lupus nephritis (LN), a subset of patients who fail to respond adequately to conventional immunosuppression. Early preclinical and emerging clinical data suggest that targeting CD73, an ecto-5'-nucleotidase involved in adenosine generation and immune regulation, may reduce renal inflammation and fibrosis. However, clinical evidence remains preliminary and limited, warranting cautious interpretation. Anti-CD73 agents are not yet part of standard care but may become adjunctive options for refractory LN pending further validation.

What the evidence shows

Lupus nephritis is a severe manifestation of systemic lupus erythematosus characterized by immune complex deposition and inflammation in the kidneys. Despite advances in immunosuppressive regimens, including mycophenolate mofetil and rituximab, a significant proportion of patients exhibit treatment resistance or relapse (Lee et al., 2026; Davies et al., 2013). This unmet need has driven exploration of novel targets such as CD73, which catalyzes the conversion of AMP to adenosine, a molecule with complex immunoregulatory roles.

Recent reviews highlight CD73 as a promising candidate due to its dual role in modulating inflammation and fibrosis pathways implicated in LN pathogenesis (Lee et al., 2026). Preclinical models demonstrate that inhibition of CD73 activity can attenuate renal immune cell infiltration and reduce pro-fibrotic signaling, potentially preserving renal function. These mechanistic insights provide a rationale for targeting CD73 in refractory LN cases where conventional B-cell or T-cell directed therapies have failed (Radhakrishnan et al., 2016).

Clinical data remain sparse but emerging. No large randomized controlled trials have yet been published specifically evaluating anti-CD73 agents in LN. However, early-phase studies in related autoimmune and inflammatory conditions suggest acceptable safety profiles and some efficacy signals. Given the complexity of LN immunopathology, anti-CD73 therapies may complement existing immunosuppressants by modulating extracellular adenosine levels and downstream signaling cascades, thereby reducing renal inflammation and fibrosis (Lee et al., 2026).

Caveats and uncertainty

The evidence supporting anti-CD73 therapies in LN is currently hypothesis-generating and largely preclinical or extrapolated from related diseases. There is a lack of robust clinical trial data directly assessing efficacy, optimal dosing, and long-term safety in LN populations. The heterogeneity of LN phenotypes and variable disease activity complicate interpretation of potential benefits.

Moreover, the role of adenosine signaling in immune regulation is complex and context-dependent, with potential for both pro- and anti-inflammatory effects. This raises concerns about unintended consequences of CD73 inhibition, including impaired tissue repair or altered immune surveillance. Existing immunosuppressive regimens remain the cornerstone of LN management, and anti-CD73 therapies should not replace established treatments outside of clinical trials (Lee et al., 2026; Davies et al., 2013).

Finally, the rarity of treatment-resistant LN and challenges in patient recruitment may limit the pace of clinical development. Biomarkers predictive of response to anti-CD73 therapy have not yet been identified, further complicating patient selection.

How this may change practice

If ongoing and future clinical studies confirm safety and efficacy, anti-CD73 therapies could emerge as adjunctive options for patients with refractory lupus nephritis who have exhausted conventional immunosuppressive strategies. This would expand the therapeutic armamentarium and potentially improve renal outcomes in a difficult-to-treat subgroup.

In clinical practice, integration of anti-CD73 agents would require careful patient selection, likely guided by biomarkers or disease phenotype, and close monitoring for adverse effects related to immune modulation. Combination approaches with existing therapies such as mycophenolate mofetil or rituximab may optimize efficacy while minimizing toxicity.

For now, nephrologists should remain informed about this evolving area but continue to rely on established evidence-based guidelines for LN management (Lee et al., 2026; Chan et al., 2010). Participation in clinical trials investigating anti-CD73 therapies is encouraged to generate high-quality data and advance care for treatment-resistant LN.


References

  1. Lee Sunhwa, et al. Advances and unmet needs in the management of proliferative lupus nephritis: evidence, guidelines, and emerging therapies. Kidney Research and Clinical Practice. 2026 DOI:10.23876/j.krcp.26.089
  2. Davies RJ, et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus. 2013 DOI:10.1177/0961203313483376
  3. Radhakrishnan Jai, et al. Faculty Opinions recommendation of Current and emerging therapies for lupus nephritis. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. 2016 DOI:10.3410/f.726413787.793519601
  4. Chan Daniel Tak Mao, et al. Mycophenolate mofetil as treatment in lupus nephritis. Lupus Nephritis. 2010 DOI:10.1093/med/9780199568055.003.0010

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team